MASLD update: Oct. 11, 2024
- Andrew M. Korda, MSHC
- Oct 11, 2024
- 1 min read
Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target
Published in International Journal of Molecular Sciences, Oct. 8, 2024
This review postulates why their modulation by GLP1-Ras may mediate the beneficial metabolic effects of these drugs, which have increased attention to their emerging role as pharmacotherapy for MASLD. By discussing the crosstalk between GLP1-Ras-FGF21-fetuin-A, this review hypothesizes that the possible modulation of fetuin-A by the novel GLP1-FGF21 dual agonist pharmacotherapy may contribute to the management of metabolic and liver diseases.
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies
Published in Biomedicines, February 2024
This review dives into the pathophysiology, risk factors, and therapeutic avenues for MASLD, emphasizing recent findings on the condition's progression and potential interventions. https://www.mdpi.com/2227-9059/12/2/397
Comments